Pelvic Ultrasonography and Sonohysterography

Published on 10/04/2015 by admin

Filed under Surgery

Last modified 10/04/2015

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 3893 times

Chapter 30 Pelvic Ultrasonography and Sonohysterography


Ultrasonography is an invaluable diagnostic tool for the assessment of uterine and pelvic pathology.1 The use of both transabdominal and transvaginal ultrasonography has become widespread because it is a safe, noninvasive, and readily available tool in the office setting. For evaluation of uterine cavity abnormalities, the diagnostic accuracy of ultrasonography is improved considerably by injecting normal saline solution into the uterine cavity during a procedure referred to as sonohysterography. For many conditions and complaints, ultrasonography has become one of the standard first steps in the diagnostic evaluation.

Surgery remains the gold standard for evaluation of the internal and external surfaces of pelvic organs, often by laparoscopy or hysteroscopy. Although these diagnostic modalities are both sensitive and specific, they are most often performed in an operating room setting under regional or general anesthesia and pose significantly greater risks and costs than ultrasonography. In addition, they cannot evaluate structures within the uterine wall and ovaries without damaging these structures. Ultrasonography and sonohysterography are two of the most important technologic advancements introduced into the practice of obstetrics and gynecology because they can improve noninvasive clinical assessment of both the surface and internal structure of the pelvic organs, and thus optimize treatment decisions.

This chapter focuses on the basic physical principles of gynecologic ultrasonography; the indications, techniques, and applications of ultrasonography and sonohysterography; and normal and abnormal pelvic findings associated with these techniques. A review of the utility of these diagnostic studies for different pathologic conditions as well as their comparative value to each other and existing gold standards are discussed.


Ultrasound Equipment Parameters

When using an ultrasound scanner, it is important to understanding the basic physical principles so that the best parameters can be set to optimize the image quality and obtain the desired information.

An ultrasound scanner obtains images by emitting a pulse of high-frequency sound and then measuring the echoes that reflect back from a boundary between two tissue structures. Sound information returning from organs and other tissues depends on the density of these structures. These echoes are electronically processed to produce images of these structures.

Ultrasound Modes

Originally, ultrasound images were displayed in one dimension, referred to as either A-mode (amplitude mode) or M-mode (motion mode). M-mode is still used to analyze cardiac motion, where ultrasound echoes are displayed as a function of distance and time as parallel vertical lines progressing from left to the right.

Today, most ultrasound images are displayed in two dimensions, referred to as B-mode (brightness mode). For this technique, also referred to as gray-scale, the axes of the display correspond to the physical coordinates of the object, and the intensity of each point on the display is proportional to the intensity of the reflected ultrasound.

A recent technologic advance, termed three-dimensional (3D) ultrasonography, uses computer software to combine multiple B-mode images in successive planes into a three-dimensional image that displays volume. If multiple volume images are shown in rapid succession, a motion video is obtained, which is sometimes referred to as 4D ultrasonography, because it shows three dimensions over time.2

An additional ultrasound approach used clinically is termed color flow Doppler ultrasonography. For this approach, a standard B-mode image is overlaid with colors derived from Doppler sounds, which represent the speed and direction of blood flowing through vessels (Fig. 30-1).


Ultrasonography Versus Sonohysterography

Transvaginal ultrasonography is the first step in evaluating the uterus, ovaries, and tubes. When a symmetric and regular endometrial stripe can be clearly imaged, the uterine cavity can be determined to be normal and endometrial thickness can be accurately determined. In contrast, when the endometrial stripe is irregular or poorly delineated, transvaginal ultrasonography alone has limited usefulness in evaluating the nature and location of endometrial cavity pathology.610 In these cases, sonohysterography greatly enhances the ability to visualize lesions that project into the uterine cavity.

Sonohysterography enhances the diagnostic accuracy of transvaginal ultrasonography by filling the endometrial cavity with fluid (usually normal saline solution) via a transcervical catheter.11 First described by Nannini in 1981 as echohysteroscopy, this technique is also referred to as saline infusion sonography.12 Sonohysterography is a simple, accurate way to detect intrauterine masses that will ultimately be evaluated histologically to differentiate endometrial polyps, submucosal leiomyomas, and endometrial carcinoma.13 This technique has several advantages over X-ray hysterosalpingography, including less pain, less cost, and no exposure to ionizing radiation.


Transvaginal ultrasound with or without sonohysterography is often one of the first diagnostic steps in the evaluation of a wide spectrum of gynecologic and obstetric conditions that can result from or cause anatomic alterations of the reproductive organs (Table 30-1). The excellent diagnostic accuracy, minimal invasiveness, and relative cost-effectiveness of these techniques have led to their widespread acceptance.

Table 30-1 Clinical Indications for Ultrasonography and Sonohysterography

  Ultrasonography Sonohysterography
Pelvic mass X  
Pelvic pain X  
Pelvic inflammatory disease X  
Lost intrauterine device X  
Infertility X X
Recurrent pregnancy loss X X
Abnormal uterine bleeding X X
To evaluate indistinct endometrium   X
To evaluate thickened endometrium   X
To monitor tamoxifen therapy   X
To predict depth of endometrial cancer invasion   X
Uterine leiomyomata
Intramural and pedunculated X  
Submucosal and intracavitary   X
Intraoperative sonohysterography   X
To disperse intrauterine adhesions   X

Pelvic Mass

Probably one of the most common indications for pelvic ultrasonography is evaluation of a pelvic mass detected on examination. The origin of the mass, usually from the uterus or ovary, can easily be determined in most cases. In some cases, the pelvic mass will be demonstrated to be nongynecologic.

Uterine Leiomyomas

Uterine leiomyomas are the most common indication for hysterectomy in the United States. Although approximately 25% of women will have symptomatic uterine leiomyomas, the cumulative incidence of leiomyomas by age 50 is nearly 70% for white women and more than 80% for black women.17

The classic sonographic appearance of a uterine leiomyoma is a spherical hypoechoic or hyperechoic area contiguous with the uterine wall.18 In some cases, calcification of leiomyomas results in irregular high-amplitude echoes. In many cases, it is difficult with transvaginal ultrasonography alone to determine whether a leiomyoma is intramural, submucosal, or intracavitary in location.

Sonohysterography can accurately identify the size, location, and depth of uterine leiomyomata (Fig. 30-2).19 This information helps predict surgical resectability, the best access for surgery (abdominal versus hysteroscopic), and the duration of surgery.

For surgical planning, uterine leiomyomas are classified into three types:

Class 3 leiomyomas are the least amenable to successful resection and are associated with significantly more complications, including uterine perforation, fluid overload, and incomplete resection.20

Pelvic Inflammatory Disease

Pelvic ultrasonography can be extremely helpful for the evaluation of women with a clinical diagnosis of pelvic inflammatory disease.22 In most patients, ultrasonography will be normal, because normal and inflamed fallopian tubes are not sonographically distinct. Some patients will have acute or chronic abnormalities that are sonographically visible, such as a pyosalpinx, hydrosalpinx, tubo-ovarian abscess, or tubo-ovarian complex (Fig. 30-3).

Abnormal Uterine Bleeding

Postmenopausal Women

Evaluation of abnormal uterine bleeding in postmenopausal women is extremely important to exclude endometrial cancer, because almost 10% will ultimately be found to have a malignancy.28 Endometrial cancer occurs in 1 to 2 per 1000 postmenopausal women per year and is one of the most common cancers in the female, exceeded in frequency only by cancers of the breast, colon, and lung. Thus, all postmenopausal women with abnormal uterine bleeding should undergo a thorough evaluation.

Ultrasonography Versus Sonohysterography

Ultrasonography and sonohysterography are sensitive noninvasive methods for detecting focal intrauterine lesions, which usually indicate carcinoma, hyperplasia, polyps, and submucosal uterine fibroids.3136 The incidence of polyps and submucosal uterine fibroids in symptomatic premenopausal women is 33% and 21%, respectively.37 If ultrasonography or sonohysterography reveals a focal lesion, this should be evaluated with a hysteroscopy/D&C rather than with a blind endometrial biopsy, because ultrasonography cannot accurately identify the nature of the lesion.

The sonographic appearance of a symmetric endometrial echo indicates that there are no focal lesions present. To reliably assess endometrial thickness, the endometrial echo must be completely seen in a longitudinal axis, surrounded by an intact hypoechoic junctional zone. The predictive value of endometrial thickness will be decreased in the presence of coexisting pathology, which can distort the endometrium or extreme angulation of the uterus.

Several studies have suggested that in postmenopausal women, endometrial thickness up to 5 mm makes endometrial pathology (i.e., endometrial hyperplasia or carcinoma) extremely unlikely, and some clinicians will therefore omit an endometrial biopsy.38 This cutoff is only useful in postmenopausal women who are not taking postmenopausal hormones such as estrogen or tamoxifen. It is also important to remember that using sonographic thickness of the endometrium to exclude endometrial carcinoma in postmenopausal women with bleeding is not 100% accurate regardless of the cutoff used.

How accurate is endometrial thickness in predicting carcinoma? Meta-analyses indicated that carcinoma will be found in approximately one third of postmenopausal women with bleeding whose endometrial thickness is greater than 5mm.39 When the endometrium is equal to or less than 5mm, only 2% to 7% will subsequently be found to have carcinoma.39,40 Reducing the cutoff to 4mm will decrease the risk of carcinoma to 1.2%.41 Because endometrial carcinoma is a curable disease when discovered early, most clinicians will perform an initial endometrial biopsy in postmenopausal women with bleeding, regardless of endometrial thickness (Fig. 30-4). If the biopsy of a patient with an endometrial thickness of 5mm or less returns as “quantity not sufficient for diagnosis,” continued surveillance is a reasonable approach.


Sonohysterography is much more effective than transvaginal ultrasound alone to detect endometrial pathology in women with abnormal uterine bleeding and thickened endometrium. In addition to clearly demonstrating the location of intracavitary lesions, sonohysterography allows for differentiation of isolated submucosal defects from more diffuse endometrial thickening.19,4244 One study of 199 postmenopausal women with abnormal bleeding found that whereas only 7% were found to have endometrial abnormalities on transvaginal ultrasound, more than 34% had abnormalities detected by sonohysterogram.45

In the past, the initial step in the evaluation of a woman with postmenopausal bleeding was an office endometrial biopsy. However, this procedure is notoriously inaccurate in the presence of focal endometrial pathology. In one study, 148 postmenopausal women with abnormal bleeding underwent aspiration endometrial biopsy, followed by sonohysterography whenever the endometrial thickness was greater than 5mm.46 Sonohysterography discovered 45 focal lesions in 81 women, 5 of which were determined to be malignancies by hysteroscopy. The initial endometrial biopsy missed 41 of these focal lesions and 3 of the 5 malignancies. The take-home message is that a blind endometrial biopsy should be avoided in women determined to have focal lesions because they often miss the pathology.

Sonohysterography is as accurate as hysteroscopy for the detection of focally growing lesions, with sensitivities for both of approximately 96%.47 However, neither modality can reliably discriminate between benign and malignant focal lesions. For this reason, histologic tissue evaluation is required whenever intrauterine pathology is discovered.

The evaluation of postmenopausal women with abnormal bleeding should utilize a combination of transvaginal ultrasonography, sonohysterography, or office endometrial biopsy when indicated, and hysteroscopy for women found to have focal lesions or abnormal biopsies (see Fig. 30-4). Utilizing ultrasonography before endometrial biopsy will avoid this uncomfortable test in women found to have focal lesions because they require a directed biopsy instead. This combination of sonohysterography and endometrial biopsy has been found to have a sensitivity of 97%, a specificity of 70%, a positive predictive value of 82%, and a negative predictive value of 94%.46

Breast Cancer Patients Receiving Tamoxifen

Tamoxifen, a selective estrogen receptor modulator, is a commonly used adjunctive therapy for women with breast cancer. Although tamoxifen acts as an estrogen antagonist in the breast, it acts as an estrogen agonist in the genital tract and is associated with endometrial hyperplasia and carcinoma. Patients taking tamoxifen have a 27% risk of developing endometrial polyps, a 9% risk of endometrial hyperplasia, and a rate of endometrial cancer two to three times higher than that of age-matched women.48,49

Neither transvaginal ultrasonography nor sonohysterography are effective screening tools in women using tamoxifen because of tamoxifen-induced subepithelial stromal hypertrophy.5052 As a result of this abnormality, there is a poor correlation between ultrasonographic measurements of endometrial thickness and abnormal endometrial proliferation or endometrial carcinoma.5355 Women taking tamoxifen should be monitored for symptoms of endometrial hyperplasia or cancer (e.g., abnormal uterine bleeding) and undergo a gynecologic examination at least yearly.56 However, because ultrasonographic screening has not been found to be effective, it is not recommended.

When a women taking tamoxifen experiences abnormal uterine bleeding, sonohysterography appears to be the most appropriate next step.57 Surgery can be avoided in approximately 14% of women who will be found to have normal endometrium with or without subendothelial cysts. The remainder of women will have focal lesions and should undergo hysteroscopically directed biopsies, because a blind endometrial biopsy in the office will often miss lesions.57

Screening of Asymptomatic Women

Premenopausal Women

Some clinicians recommend screening asymptomatic women with transvaginal ultrasonography, sonohysterography, or endometrial biopsy.58 One study found that approximately 10% of asymptomatic premenopausal women have uterine polyps and 1% have intracavitary fibroids, compared to 33% and 21% of symptomatic women, respectively.59 However, it is uncertain how much of this pathology is actually associated with health risks and how much will regress spontaneously.60 The concern is that such screening is likely to lead to some unnecessary surgical intervention. Until more information is available, universal screening is not recommended.61

Postmenopausal Women

Transvaginal ultrasound has not been shown to be a useful screening test in asymptomatic postmenopausal women regardless of their use of hormone treatment. One study reported that more than 35% of asymptomatic postmenopausal women have focal endometrial pathology by sonohysterography.45 Although the incidence of endometrial pathology in postmenopausal women with bleeding is relatively high, the incidence of life-threatening focal endometrial lesions in asymptomatic women is likely to be low.61 More importantly, the discriminatory value of endometrial thickness is lost in these asymptomatic women. One study of 448 postmenopausal women, half of whom were receiving estrogen replacement therapy, found that although endometrial thickness less than 5 mm was highly predictive of normal endometrium (negative predictive value, 99%), endometrial thickness greater than 5 mm was unlikely to indicate pathology (positive predictive value, 9%).60 A study of 1926 asymptomatic postmenopausal women showed similar results using a 6 mm threshold for endometrial thickness.63 Screening asymptomatic postmenopausal women is not currently recommended.

Endometrial Carcinoma

Predicting Depth of Invasion

Histology, tumor grade, depth of myometrial invasion, and tumor size are well known prognostic factors for lymph node metastasis by endometrial cancer but are difficult to predict preoperatively.66,67 Magnetic resonance imaging is effective in predicting the depth of myometrial invasion and endometrial cancer tumor size but is expensive and is not universally available. An alternative approach is sonohysterography to determine the depth of endometrial invasion; patients with deeply invasive disease can be referred to a gynecologic oncologist.

After endometrial carcinoma has been diagnosed histologically on biopsy, sonohysterography has been suggested as a way to accurately determine the degree of myometrial invasion.68 In a small study of 19 endometrial adenocarcinoma patients, sonohysterography performed before hysterectomy was able to predict the exact depth of myometrial invasion in 15 (94%) cases, suggesting a potential role for this technique in preoperative staging of endometrial carcinoma. More studies are necessary before widespread application of this approach.

Risk of Disbursing Malignant Cells

There is a concern that procedures that distend the uterus with fluid media (i.e., hysteroscopy, hysterosalpingography, and sonohysterography) could flush malignant endometrial cells into uterine vessels or through the tubes into the peritoneal cavity, thus adversely affecting the prognosis for patients with endometrial carcinoma. One study of hysterograms in patients with endometrial cancer found no correlation between intravasation of contrast medium into lymphatics and veins and subsequent 5-year survival rates.69 A sonohysterogram study of women with stage I endometrial carcinoma showed that infusion of 10 to 20mL of saline solution resulted in saline spillage from the fallopian tubes in 5 of 14 patients; in 1 patient this fluid contained malignant cells.70 These findings suggest that sonohysterography might have a small risk of cancer dissemination, although the prognostic significance of flushing endometrial cancer cells in the peritoneal cavity remains uncertain. Additional studies are warranted.

Infertility and Recurrent Pregnancy Loss

Initial Evaluation

Abnormalities related to the uterus or fallopian tubes are present in a large number of infertile women. For the infertile patient, hysterosalpingogram (HSG) has traditionally been the first step in evaluation of the uterine cavity and tubes. Surgical evaluation with laparoscopy or hysteroscopy is used when intra-abdominal pathology is suspected or when all other diagnostic tests are normal. Recent investigations have suggested that pelvic ultrasonography and sonohysterography might also be valuable in the assessment of the infertile woman.

Transvaginal ultrasonography, with sonohysterography when indicated, is a useful diagnostic procedure for the initial evaluation of infertile patients.71 Congenital and acquired uterine pathology is present in up to 10% of infertile couples and 15% to 55% of those with recurrent pregnancy loss. Pathologic conditions of the uterus that can be detected with ultrasonography and sonohysterography include müllerian and diethylstilbestrol-related anomalies, uterine fibroids, endometrial polyps, and Asherman’s syndrome. Other fertility-related conditions that can be detected include hydrosalpinges (see Fig. 30-3) and polycystic ovaries (Fig. 30-5).

Sonohysterography can be used to thoroughly evaluate the endometrial cavity and has been shown to be as accurate as diagnostic hysteroscopy in detecting pathology. In a study of 72 infertile women, 11% were found to have cavitary lesions with both HSG and hysteroscopy; there was no statistical difference in pregnancy outcome between these two techniques for uterine evaluation.72